|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910139507003321 |
|
|
Titolo |
Critical pathways to success in CNS drug development [[electronic resource] /] / Neal R. Cutler ... [et al.] |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Chichester, UK ; ; Hoboken, NJ, : Wiley-Blackwell, 2010 |
|
|
|
|
|
|
|
ISBN |
|
1-282-49126-1 |
9786612491269 |
1-4443-1857-8 |
1-4443-1858-6 |
|
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (273 p.) |
|
|
|
|
|
|
Altri autori (Persone) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Neuropsychopharmacology |
Drug development |
Critical path analysis |
Central nervous system - Effect of drugs on - Research - Methodology |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Description based upon print version of record. |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references and index. |
|
|
|
|
|
|
Nota di contenuto |
|
Critical Pathwaysto Success in CNSDrug Development; Contents; Acknowledgments; Foreword; 1 The impending crisis in CNS drug development; 2 Animal models and procedures for CNS disorders; 3 Preclinical antecedents to early human clinical trials; 4 Biomarkers and surrogate markers in drug development; 5 Neuroimaging and cognitive assessments in early drug development; 6 Bridging and CSF studies; 7 A case study from preclinical to early clinical trials; Index |
|
|
|
|
|
|
|
|
Sommario/riassunto |
|
Covering the latest advances in CNS drug development, this book will guide all those involved in pre-clinical to early clinical trials. The authors describe how recent innovations can accelerate the development of novel CNS compounds, improve early detection of efficacy and toxicity signals, and increase the safety of later-stage clinical trials. The current crisis in the drug development industry is critically reviewed, as well as the steps needed to correct the problems, including new government-backed regulations and industry-based innovations designed to accelerate CNS drug development i |
|
|
|
|
|
|
|